Skip to main content

Ventipulmin Syrup (clenbuterol hydrochloride)

This page contains information on Ventipulmin Syrup (clenbuterol hydrochloride) for veterinary use.
The information provided typically includes the following:
  • Ventipulmin Syrup (clenbuterol hydrochloride) Indications
  • Warnings and cautions for Ventipulmin Syrup (clenbuterol hydrochloride)
  • Direction and dosage information for Ventipulmin Syrup (clenbuterol hydrochloride)

Ventipulmin Syrup (clenbuterol hydrochloride)

This treatment applies to the following species:
Company: Boehringer Ingelheim Animal Health

(clenbuterol HCl)

Approved by FDA under NADA# 140-973

For oral use in horses only

Ventipulmin Syrup (clenbuterol hydrochloride) Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Ventipulmin Syrup (clenbuterol hydrochloride) Caution

Federal law prohibits the extra label use of this drug in food animals.

Each mL contains: Clenbuterol HCl 72.5 mcg

Description

Clenbuterol (4-amino-alpha-[(tert-butylamino) methyl]• 3, 5-dichlorobenzyl alcohol hydrochloride) is a beta-2-adrenergic agonist which provides bronchodilating properties as well as other effects, with minimum effect on the cardiovascular system. It is provided as a colorless, palatable syrup. VENTIPULMIN Syrup (clenbuterol hydrochloride) is antagonized by beta-adrenergic blocking agents.

Ventipulmin Syrup (clenbuterol hydrochloride) Indications

VENTIPULMIN Syrup (clenbuterol hydrochloride) is indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Contraindications

VENTIPULMIN Syrup antagonizes the effects of prostaglandin F2α and oxytocin. VENTIPULMIN Syrup should not be used in pregnant mares near term. Because tachycardia may occur, VENTIPULMIN Syrup should not be used in horses suspected of having cardiovascular impairment.

Warning

The effect on reproduction in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended.

Human Warnings: Not for use in humans. Do not use in horses intended for human consumption. Keep out of reach of children. In case of accidental ingestion, contact a physician immediately. Ingestion of VENTIPULMIN Syrup may cause undesirable reactions. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Dosage and Administration

Administer orally twice a day (b.i.d.).

Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily.

Dosage Schedule:

Initial dosage: administer 0.5 mL/100 lbs (0.8 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.0 mL/100 lbs (1.6 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.5 mL/100 lbs (2.4 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 2.0 mL/100 lbs (3.2 mcg/kg) for 3 days (6 treatments);

If no improvement, horse is non-responsive to clenbuterol and treatment should be discontinued.

Recommended duration of treatment at effective dose is 30 days. At the end of this 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, the 30-day treatment regimen may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated.

Directions for Administration: Remove safety cap and seal; replace with enclosed plastic dispensing cap. Remove cover from dispensing tip and connect syringe (without needle). Draw out appropriate volume of VENTIPULMIN Syrup. Administer orally to the horse. Replace cover on dispensing tip to prevent leakage.

Dosage Calculation Chart

Lbs Body Weight

mL/treatment at 0.5 mL/100#
(0.8 mcg/kg)

mL/treatment at 1.0 mL/100#
(1.6 mcg/kg)

mL/treatment at 1.5 mL/100#
(2.4 mcg/kg)

mL/treatment at 2.0 mL/100#
(3.2 mcg/kg)

500

2.5

5.0

7.5

10.0

600

3.0

6.0

9.0

12.0

700

3.5

7.0

10.5

14.0

800

4.0

8.0

12.0

16.0

900

4.5

9.0

13.5

18.0

1000

5.0

10.0

15.0

20.0

1100

5.5

11.0

16.5

22.0

1200

6.0

12.0

18.0

24.0

1300

6.5

13.0

19.5

26.0

1400

7.0

14.0

21.0

28.0

1500

7.5

15.0

22.5

30.0

1600

8.0

16.0

24.0

32.0

1700

8.5

17.0

25.5

34.0

1800

9.0

18.0

27.0

36.0

Administer two treatments per day.

Precaution: The safety cap should be placed on the bottle when not in use.

Adverse Reactions

Mild sweating, muscle tremor, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment. May cause elevated creatine kinase (CK) serum levels. Ataxia was observed in 3 out of 239 horses (1.3%) in clinical studies.

To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer lngelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or on line at www.fda.gov/reportanimalae.

How Supplied

VENTIPULMIN Syrup is available in 100 mL and 330 mL plastic bottles containing 72.5 mcg clenbuterol HCl per mL.

NDC 0010-3017-02 - 100 mL, NDC 0010-3017-03 - 330 mL

Storage

Store at or below 25°C (77°F). Avoid freezing.

VENTIPULMIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH.

Marketed by: Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096

Made in Mexico

301701-05

US-EQU-0082-2021

CPN: 1028113.6

BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
3239 SATELLITE BLVD., BLDG 500, DULUTH, GA, 30096
Telephone:   800-325-9167
Customer Service:   800-243-0127
Fax:   816-236-2717
Website:   www.boehringer-ingelheim.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

Copyright © 2022 Animalytix LLC. Updated: 2022-06-01